T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab.
T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab.
复制标题
DOI：
10.1136/jitc-2021-002521
复制
发表时间：
2021-05
影响因子：
10.9
通讯作者：
Naisbitt D
中科院分区：
文献类型：
--
作者：
Hammond S;Olsson-Brown A;Gardner J;Thomson P;Ali SE;Jolly C;Carr D;Ressel L;Pirmohamed M;Naisbitt D
许多与免疫检查点抑制剂(ICI)治疗相关的不良反应是由免疫驱动的，可能需要停止ICI。在此，我们介绍了一位患者，他曾多次使用放射造影剂氨基三氮酸盐，但没有问题，但在联合使用阿替唑珠单抗后出现了史蒂文斯-约翰逊综合征反应。因果关系通过对氨基三氮化合物的阳性再挑战和涉及T细胞的实验室研究得到确认。重要的是，在耐受性诱导连续体方面，阿替唑单抗的引入似乎已经改变了对氨基三氮酸的免疫反应。概念验证研究表明，在体外(健康供者)和体内(ICI患者)注射ICIS后，对替代抗原小组的召回反应增强。我们的发现强调了在ICIS患者出现免疫介导的不良反应时考虑所有伴随药物的重要性。在发生一些与免疫相关的不良反应时，确定ICIS改变了人们的看法的罪魁祸首抗原形成实体可能是至关重要的，而不是简单地将因果关系归因于ICI本身，以优化患者安全和恶性肿瘤的治疗。
Many adverse reactions associated with immune checkpoint inhibitor (ICI) treatments are immunologically driven and may necessitate discontinuation of the ICI. Herein, we present a patient who had been administered the radio contrast media amidotrizoate multiple times without issue but who then developed a Stevens-Johnson syndrome reaction after coadministration of atezolizumab. Causality was confirmed by a positive re-challenge with amidotrizoate and laboratory investigations that implicated T cells. Importantly, the introduction of atezolizumab appears to have altered the immunologic response to amidotrizoate in terms of the tolerance–elicitation continuum. Proof of concept studies demonstrated enhancement of recall responses to a surrogate antigen panel following in-vitro (healthy donors) and in-vivo (ICI patients) administrations of ICIs. Our findings highlight the importance of considering all concomitant medications in patients on ICIs who develop immune-mediated adverse reactions. In the event of some immune-related adverse reactions, it may be critical to identify the culprit antigen-forming entity that the ICIs have altered the perception of rather than simply attribute causality to the ICI itself in order to optimize both patient safety and treatment of malignancies.
登录
查看更多内容
影响因子：
14.2
作者：
Wieder, Thomas;Eigentler, Thomas;Roecken, Martin
通讯作者：
Roecken, Martin
影响因子：
13.5
作者：
Metushi, Imir G.;Hayes, M. Anthony;Uetrecht, Jack
通讯作者：
Uetrecht, Jack
DOI：
10.4049/jimmunol.1302720
发表时间：
2014-03-15
期刊：
Journal of immunology (Baltimore, Md. : 1950)
影响因子：
--
作者：
Gibson A;Ogese M;Sullivan A;Wang E;Saide K;Whitaker P;Peckham D;Faulkner L;Park BK;Naisbitt DJ
通讯作者：
Naisbitt DJ
DOI：
10.1016/j.jaip.2017.01.025
发表时间：
2017-05
期刊：
The journal of allergy and clinical immunology. In practice
影响因子：
--
作者：
Peter JG;Lehloenya R;Dlamini S;Risma K;White KD;Konvinse KC;Phillips EJ
通讯作者：
Phillips EJ
影响因子：
4
作者：
Cui, Wanyuan;Cotter, Chantal;Popat, Sanjay
通讯作者：
Popat, Sanjay